Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Operating Expenses: 2009-2025

Historic Operating Expenses for Ani Pharmaceuticals (ANIP) over the last 17 years, with Sep 2025 value amounting to $191.6 million.

  • Ani Pharmaceuticals' Operating Expenses rose 13.46% to $191.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $754.9 million, marking a year-over-year increase of 38.83%. This contributed to the annual value of $613.8 million for FY2024, which is 39.55% up from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Operating Expenses is $191.6 million, which was down 2.99% from $197.5 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Operating Expenses ranged from a high of $197.5 million in Q2 2025 and a low of $51.5 million during Q1 2021.
  • In the last 3 years, Ani Pharmaceuticals' Operating Expenses had a median value of $132.9 million in 2024 and averaged $146.7 million.
  • In the last 5 years, Ani Pharmaceuticals' Operating Expenses dropped by 10.66% in 2021 and then skyrocketed by 62.55% in 2022.
  • Ani Pharmaceuticals' Operating Expenses (Quarterly) stood at $84.7 million in 2021, then increased by 9.17% to $92.4 million in 2022, then soared by 35.19% to $124.9 million in 2023, then skyrocketed by 56.05% to $195.0 million in 2024, then rose by 13.46% to $191.6 million in 2025.
  • Its Operating Expenses stands at $191.6 million for Q3 2025, versus $197.5 million for Q2 2025 and $170.9 million for Q1 2025.